Patents Issued in December 21, 2017
-
Publication number: 20170360890Abstract: The present invention provides a method for treating multiple sclerosis (MS), and for reducing flu-like symptoms associated with administration of an interferon to a patient with MS. The method involves intramuscularly administering the interferon to the MS patient according to an escalating dosing regimen in weeks 1 to 3, and a full therapeutically effective dose of interferon in week 4. In one embodiment of the invention, the escalating dosing regimen comprises administering one quarter of the therapeutically effective dose in week 1, half of the therapeutically effective dose in week 2, and three-quarters of the therapeutically effective dose in week 3. Also provided are titration packages for enabling compliance with a regimen of changing dosage of an interferon over a period of time.Type: ApplicationFiled: September 5, 2017Publication date: December 21, 2017Applicant: Biogen Inc.Inventor: Aaron DEYKIN
-
Publication number: 20170360891Abstract: The present invention provides a stable, isotonic, aqueous solution formulation comprising: (i) 0.1-0.5 mg/mL alpha-type interferon, preferably pegylated alpha-type interferon; (ii) 20 mM Acetate buffer system to maintain a pH of 6.0±0.5; (iii) 5-20 mM L-methionine; (iv) 120-150 mM sodium chloride; (v) 0.01-0.07 percent by weight of a surfactant effective to stabilize the alpha-type interferon, preferably pegylated alpha-type interferon against loss of its activity and (vi) an amount of water for injection sufficient to prepare a solution of the above-listed ingredients.Type: ApplicationFiled: March 23, 2017Publication date: December 21, 2017Applicant: Hoffmann-La Roche Inc.Inventors: Ulla Grauschopf, Michael Adler, Hanns-Christian Mahler, Felix Heise, Susanne Baroth
-
Publication number: 20170360892Abstract: The present invention relates to a novel glucagon derivative peptide, and a composition for preventing or treating hypoglycemia containing the novel glucagon derivative peptide as an active ingredient. The glucagon derivative according to the present invention has improved physical properties due to the change in isoelectric point (pI) while being capable of maintaining an activity on glucagon receptors, and thus can improve patient compliance when used as a hypoglycemic agent, and is also suitable for administration in combination with other anti-obesity agents. Accordingly, the glucagon derivative according to the present invention can be effectively used for the prevention and treatment of hypoglycemia and obesity.Type: ApplicationFiled: December 30, 2015Publication date: December 21, 2017Applicant: HANMI PHARM. CO., LTD.Inventors: Jung Kuk KIM, Jong Min LEE, Sang Yun KIM, Sung Min BAE, Sung Youb JUNG, Se Chang KWON
-
Publication number: 20170360893Abstract: Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (GLP-1) receptor and the glucagon (GCG) receptor, and the use of such GLP-1 receptor/GCG receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesityType: ApplicationFiled: October 22, 2015Publication date: December 21, 2017Applicant: MERCK SHARP & DOHME CORP.Inventors: Elisabetta Bianchi, Paul E. Carrington, Qiaolin Deng, Ravi Nargund, Federica Orvieto, Anandan Palani, Antonello Pessi, Thomas Joseph Tucker, Chengwei Wu
-
Publication number: 20170360894Abstract: The disclosure relates to a dosage forms and combinations of dosage forms useful for effective oral administration of drugs which are otherwise unsuitable for oral administration, owing to acid- and/or protease-mediated degradation. The dosage forms include a self-microemulsifying drug delivery system (SMEDDS) with which the drug is combined and an antacid. When co-administered to a mammal, the dosage form(s) can prevent drug degradation by the strong acid and digestive enzymes normally present in the gastric environment, and can improve water-soluble drug absorption in gastrointestinal (GI) tract. The dosage forms can be used to effectively administer insulin by an oral route, for example, such as in the form of a powder that can be stored for long periods and reconstituted with water or another fluid shortly before administration.Type: ApplicationFiled: November 4, 2015Publication date: December 21, 2017Applicant: InnoPharmax, Inc.Inventors: Yu-Tsai YANG, Jong-Jing WANG, Pei-Jing HSU, Li-Chien CHANG, Wei-Hua HAO, Chang-Shan HSU
-
Publication number: 20170360895Abstract: A pharmaceutical formulation comprises an insulin analogue or a physiologically acceptable salt thereof, wherein the insulin analogue or a physiologically acceptable salt thereof contains an insulin A-chain sequence that contains paired Histidine substitutions at A4 and A8, and optionally a substitution at A21. The formulation further contains a pharmaceutically acceptable buffer containing at least about 4 zinc ions per 6 insulin analogue molecules. The formulation forms a long-acting zinc-dependent subcutaneous depot upon subcutaneous injection. In a zinc-free formulation, the insulin analogue monomer exhibits decreased affinity for the Insulin-like Growth Factor receptor and at least 20% of the affinity for the insulin receptor of the same species, in comparison to an otherwise identical insulin or insulin analogue that does not contain the HisA4 and HisA8 substitutions.Type: ApplicationFiled: April 28, 2017Publication date: December 21, 2017Inventor: Michael Weiss
-
Publication number: 20170360896Abstract: The present invention is directed to alpha-MSH analogues for treatment of inflammatory disease.Type: ApplicationFiled: October 28, 2015Publication date: December 21, 2017Inventor: Philippe WOLGEN
-
Publication number: 20170360897Abstract: The present invention provides a group of polypeptides and a complex formed by the polypeptides and human serum albumin, a method for improving the solubility of the group of polypeptides in a salt solution by combining the polypeptides with human serum albumin, a method for preparing the complex formed by the group of polypeptides and human serum albumin, and an application of the group of polypeptides and the complex formed by the polypeptides and human serum albumin in the preparation of drugs for suppressing tumor metastasis and treating leukemia.Type: ApplicationFiled: July 1, 2015Publication date: December 21, 2017Inventors: Chen Wang, Hongyang Duan, Yanlian Yang, Haiyan Xu, Xiaojin Li, Hua Guo, Hanyi Xie, Yue Yu
-
Publication number: 20170360898Abstract: A method of reducing blood glucose in a subject has been developed. In preferred embodiments, the method involves administering to the subject a specific activator of endogenous mitogen-activated protein kinase kinase 6 (MKK3), mitogen-activated protein kinase kinase 6 (MKK4), mitogen-activated protein kinase kinase 6 (MKK6), p38 mitogen-activated protein kinase (p38MAPK), mitogen-activated kinase-activated protein kinase 2 (MK2), or a combination thereof, in an effective amount to reduce blood glucose in a subject. In other embodiments, the method involves administering to the subject a specific activator to increase X-box binding protein 1 (XBP1) phosphorylation on Thr48 and Ser61 in an effective amount to reduce blood glucose in the subject. Methods of identifying agents for reducing blood glucose in a subject are also provided.Type: ApplicationFiled: August 8, 2017Publication date: December 21, 2017Inventors: Umut Ozcan, Jaemin Lee
-
Publication number: 20170360899Abstract: The present disclosure provides a method of treating seizure in a subject having aberrant alkaline phosphatase activities, comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to the subject.Type: ApplicationFiled: December 4, 2015Publication date: December 21, 2017Inventors: Andre MAROZSAN, Denise DEVORE, Susan LIU-CHEN
-
Publication number: 20170360900Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH <4.5) and basic (pH >7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.Type: ApplicationFiled: December 2, 2015Publication date: December 21, 2017Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
-
Publication number: 20170360901Abstract: The present application provides for compositions comprising ?-galactosidase A in combination with an active site-specific chaperone for the ?-galactosidase A, and methods for treating Fabry disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an ?-galactosidase A enzyme formulation.Type: ApplicationFiled: June 30, 2017Publication date: December 21, 2017Inventors: Richie Khanna, Kenneth Valenzano, Susan Elizabeth Fowles
-
Publication number: 20170360902Abstract: Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilising agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 ?m which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.Type: ApplicationFiled: December 18, 2015Publication date: December 21, 2017Inventors: DAVIDA BLACKMAN, STACY PLUM, WILLIAM GARZON-RODRIGUEZ, MARTIN ROBITAILLE, BETTY YU
-
Publication number: 20170360903Abstract: The present invention is directed to novel systems and methods for treating dermal inflammatory disorders, such as psoriasis.Type: ApplicationFiled: June 16, 2017Publication date: December 21, 2017Inventor: Arthur Clapp
-
Publication number: 20170360904Abstract: Provided are methods for repairing a wound or inducing the proliferative phase of a wound comprising administering a composition comprising a protease mixture comprising collagenases and a neutral protease to the wound in an amount effective for repair of wound tissue or for inducing the proliferative phase in the wound.Type: ApplicationFiled: December 10, 2015Publication date: December 21, 2017Applicant: SMITH & NEPHEW, INC.Inventors: Ira HERMAN, Vincent RONFARD, Lei SHI
-
Publication number: 20170360905Abstract: The present invention provides, among other things, a conjugated C1-INH for improved treatment of complement-mediated disorders, including hereditary angioedema (HAE). In some embodiments, a conjugated C1-INH provided by the present invention is a PEGylated C1-INH. In some embodiments, a conjugated C1-INH provided by the present invention is a polysialic acid (PSA) conjugated C1-INH.Type: ApplicationFiled: April 4, 2017Publication date: December 21, 2017Inventors: Kevin Holmes, Angela Norton, Clark Pan
-
Publication number: 20170360906Abstract: This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sda or SDa-like glycans derived from the porcine ?1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and/or reduced or no endogenous ?-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.Type: ApplicationFiled: April 24, 2017Publication date: December 21, 2017Applicant: Mayo Foundation for Medical Education and ResearchInventors: Christopher G.A. McGregor, Guerard W. Byrne
-
Publication number: 20170360907Abstract: ILC2 cells play a role in the pathogenesis of graft versus host disease (GvHD) and idiopathic pneumonia syndrome (IPS), both conditions associated with allogeneic stem cell transplantation. Infusion of IL-33 activated ILC2 cells into patients with ongoing GvHD or IPS, or prior to onset of GvHD or IPS in susceptible patients, substantially ameliorates the disease and improves survival.Type: ApplicationFiled: December 4, 2015Publication date: December 21, 2017Inventors: Jonathan Serody, James Coghill, Danny Bruce, Bruce Blazar, Heather Stefanski, Benjamin Vincent
-
Publication number: 20170360908Abstract: The present invention aims to provide a vaccine pharmaceutical composition universally usable for induction of cellular immunity against various antigens and exerting a high cellular immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing cellular immunity, containing: an antigen; and a first cellular immunity induction promoter that is a bisphosphonate.Type: ApplicationFiled: September 2, 2015Publication date: December 21, 2017Applicant: NITTO DENKO CORPORATIONInventors: Takuya SHISHIDO, Daisuke ASARI, Mitsuhiko HORI
-
Publication number: 20170360909Abstract: A method of manipulating allogeneic cells for use in allogeneic cell therapy providing a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism, or “Mirror Effect”. In contrast to current allogeneic cell therapy protocols where T-cells in the graft mediate the beneficial graft vs. tumor (GVT) and detrimental graft vs. host (GVH) effects, the allogeneic cells of the present invention stimulate host T-cells to mediate the “mirror” of these effects. The mirror of the GVT effect is the host vs. tumor (HVT) effect. The “mirror” of the GVH effect is the host vs. graft (HVG) effect The anti-tumor HVT effect occurs in conjunction with a non-toxic HVG rejection effect. The highly activated allogeneic cells of the invention can be used to stimulate host immunity in a complete HLA mis-matched setting in a patient.Type: ApplicationFiled: August 30, 2017Publication date: December 21, 2017Inventor: Michael Har-Noy
-
Publication number: 20170360910Abstract: Chimeric antigen receptors for use in treating malignant melanoma and other cancers expressing CS1 are described.Type: ApplicationFiled: December 7, 2015Publication date: December 21, 2017Inventors: Xiuli Wang, Stephen J. Forman
-
Publication number: 20170360911Abstract: The purpose of the present invention is to provide: a detection agent for specifically detecting a cancer stem cell; a tumor antigen peptide specifically presented by cancer stem cells; a medicinal composition useful in preventing and/or treating cancer, said medicinal composition comprising the aforementioned tumor antigen peptide as an active ingredient; a method for screening the tumor antigen peptide; etc. To achieve the above-mentioned purpose, provided are: peptides represented by YO-XO-ZO; a polyepitope peptide consisting of a plurality of epitope peptides connected together, said polyepitope peptide containing at least one of the above-mentioned peptides as one of the epitope peptides; a polynucleotide encoding the aforementioned peptides and/or polyepitope peptide; a medicinal composition comprising the same as an active ingredient; a prophylactic and/or therapeutic agent for cancer characterized by inducing CTL; etc.Type: ApplicationFiled: December 8, 2015Publication date: December 21, 2017Applicants: Sapporo Medical University, Sumitomo Dainippon Pharma Co., Ltd.Inventors: Noriyuki Sato, Toshihiko Torigoe, Yoshihiko Hirohashi, Takayuki Kanaseki, Sho Miyamoto, Vitaly Kochin, Masashi Goto
-
Publication number: 20170360912Abstract: An hydrogel comprising chitosan and two weak bases having different pKb values. In some embodiments, one of the weak bases if sodium hydrogen carbonate (SHC). Also, use of the hydrogel in medical and cosmetic treatments.Type: ApplicationFiled: December 17, 2015Publication date: December 21, 2017Inventors: Sophie Lerouge, Elias Assaad, Caroline Ceccaldi, Anne Monette, Rejean Lapointe
-
Publication number: 20170360913Abstract: The present invention includes compositions and methods for modifying a T cell with a nucleic acid encoding a switch molecule comprising an extracellular domain comprising a membrane receptor or fragment thereof and an intracellular domain comprising a signaling receptor or fragment thereof. In one aspect, a method comprises introducing a nucleic acid encoding a switch molecule and a nucleic acid encoding a soluble fusion protein and/or a nucleic acid encoding a bispecific antibody into a population of cells comprising T cells, wherein the T cells transiently expresses the switch molecule and soluble fusion protein or bispecific antibody. In other aspect, compositions of T cells and methods of treating a disease or condition, such as cancer or an autoimmune disease, are also included.Type: ApplicationFiled: October 30, 2015Publication date: December 21, 2017Applicant: The Trustees of the University of PennsylaniaInventors: Yangbing ZHAO, Carl H. JUNE, Xiaojun LIU
-
Publication number: 20170360914Abstract: The invention relates to a peptide of 15 to 20 amino acids deriving from TERT protein, which peptide is capable of (i) binding to HLA class II and (ii) stimulating a CD4 Th response. These universal cancer peptides are especially useful in anti-tumor immunotherapy and immunomonitoring.Type: ApplicationFiled: May 31, 2017Publication date: December 21, 2017Applicants: INVECTYS, Universite De Franche-Comte, Centre Hospitalier Regional Universitaire De BesanconInventors: Pierre Langlade Demoyen, Olivier Adotevi, Magalie Dosset
-
Publication number: 20170360915Abstract: Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.Type: ApplicationFiled: May 24, 2017Publication date: December 21, 2017Applicant: GlaxoSmithKline Biologicals SAInventors: Mario CONTORNI, Lorenzo TARLI
-
Publication number: 20170360916Abstract: The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way they when cloned and expressed in the vector virus, the present in the 5? region nucleotides present in the 5? edge of the gene NS1 of this vector virus or of other virus or equivalent functional sequences, and in its 3? region, the correspondent genome region in the whole or part of the spheres of the steam and anchor of the protein E of this vector virus or equivalent functional sequences, and not comprising the structure and the replication of the mention vector virus; (b) insertion of the modified heterolog sequences in (a) in the intergene region at the structural protein E level and of constructural NS1 vector virus; (c) obtention of the non pathogenic recombinant virus and owner of the immunologic properties, having theType: ApplicationFiled: December 14, 2016Publication date: December 21, 2017Inventors: Myrna Cristina Bonaldo, Ricardo Galler
-
Publication number: 20170360917Abstract: The present invention relates to dengue virus vaccine compositions comprising a first and a second dengue vaccine, wherein the first dengue vaccine comprises at least one live, 5 attenuated dengue virus or live, attenuated chimeric dengue virus and the second dengue vaccine is a recombinant dengue subunit vaccine, a DNA vaccine, a conjugate vaccine, or an inactivated dengue vaccine; wherein the genome of the live attenuated dengue virus or the live attenuated chimeric dengue virus comprises a 30 nucleotide deletion of the TL2 stem-loop structure of the 3? untranslated region. The dengue virus vaccine compositions of the invention may further 10 comprise one or more adjuvants. In preferred embodiments of the invention, the first and the second dengue vaccine are tetravalent.Type: ApplicationFiled: December 18, 2015Publication date: December 21, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Danilo R. Casimiro, Andrew Bett, Beth-Ann Griswold Coller, Govindarajan Dhanasekaran, Ramesh V. Chintala
-
Publication number: 20170360918Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.Type: ApplicationFiled: December 15, 2015Publication date: December 21, 2017Inventors: W. Ian LIPKIN, Thomas BRIESE, Nischay Mishra, Eran Bacharach, Avi Eldar
-
Publication number: 20170360919Abstract: The present application relates to the field of immunology, in particular, a vaccine composition of respiratory syncytial virus (RSV) surface proteins, Fusion (F) and Glycoprotein (G) proteins subunit vaccine preferentially mixed with the immune cell targeting and enhancer, nanoemulsion to induce a protective immune response and avoid vaccine-induce disease enhancement.Type: ApplicationFiled: January 27, 2017Publication date: December 21, 2017Applicant: NanoBio CorporationInventors: Ali I. Fattom, Tarek Hamouda, Vira Bitko, James R. Baker, JR.
-
Publication number: 20170360920Abstract: Described herein are methods of preventing or treating a HIV infection comprising administering to a mammal in need thereof, a pharmaceutically effective amount of a CD8+ T cell vaccine composition. Such methods comprising using CD8+ T cells which have been pre-stimulated with at least one HIV epitope, to thereby enhance a CD8+ T cell immune response against HIV in said mammal.Type: ApplicationFiled: November 20, 2015Publication date: December 21, 2017Inventors: Robert Siliciano, Kai Deng, Liang Shan
-
Publication number: 20170360921Abstract: Embodiments of the present invention relate to an infectious bronchitis virus (IBV) and an immunogenic composition comprising an IBV, respectively, wherein the ORF 3a and/or the ORF 3b and/or the ORF 5a and/or the ORF 5b is inactivated. Furthermore, aspects of the present invention relate to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, embodiments of the present invention relate to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the embodiments of the present invention.Type: ApplicationFiled: June 14, 2017Publication date: December 21, 2017Inventors: Petrus ROTTIER, Stefanus VAN BEURDEN, Monique VERHEIJE, Egbert MUNDT
-
Publication number: 20170360922Abstract: The present invention relates to formulations and methods for preventing food allergies in a subject. Embodiments of the invention provide for administration of allergens from eight types of food that cause food allergies in western societies: peanut, tree nuts, milk, egg, soy, wheat, fish, and shellfish. The allergens may be provided directly to the subject, or to the subject's mother, who may be pregnant or nursing.Type: ApplicationFiled: June 21, 2017Publication date: December 21, 2017Inventor: Paul Turke
-
Publication number: 20170360923Abstract: The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may include, but are not limited to: inactivated pathogens, attenuated pathogens, subunits, recombinant expression vectors, plasmids or combinations thereof. The animals may include, but are not limited to: humans, murine, canines, felines, equines, porcines, ovines, caprines and bovines.Type: ApplicationFiled: June 15, 2017Publication date: December 21, 2017Applicants: MERIAL INC., Sanofi PasteurInventors: Guillaume Rigaut, Alexis Guy André Lucien Parisot, Karelle De Luca, Christine Michele Pierrette Andreoni, Lydie Remolue, Marie Garinot, Jean-François Cotte, Patricia Probeck-Quellec, Jean Haensler, Véronique Chambon, Philippe Talaga
-
Publication number: 20170360924Abstract: Glycosphingolipids (GSLs) bearing ?-glucose (?-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with ?-glucose (?-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with ?-galactose (?-Gal) are disclosed. GSLs bearing ?-glucose (?-Glc) and derivatives of ?-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with ?-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with ?-Glc and derivatives thereof are provided.Type: ApplicationFiled: August 29, 2017Publication date: December 21, 2017Inventors: Chi-Huey WONG, Alice L. YU, Kun-Hsien LIN, Tai-Na WU
-
Publication number: 20170360925Abstract: Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.Type: ApplicationFiled: August 31, 2017Publication date: December 21, 2017Applicant: Nant Holdings IP, LLCInventors: Kayvan NIAZI, Shahrooz RABIZADEH, Justin GOLOVATO, Patrick Soon-Shiong, Anne-Laure LE NY, Oleksandr BUZKO
-
Publication number: 20170360926Abstract: The invention provides methods for treating patients with anti-?4?7 antibody comprising predicting outcome of the antibody therapy. The invention relates to the identification of patients who can respond to therapy comprising an anti-a4?7 antibody.Type: ApplicationFiled: December 23, 2015Publication date: December 21, 2017Inventors: Maria Rosario, Timothy L. Wyant, Brihad Abhyankar
-
Publication number: 20170360927Abstract: Provided are methods of diagnosing IgA nephropathy in a subject. Optionally, the methods comprise isolating an IgG from the subject and determining whether the IgG binds to a galactose-deficient IgA1. Optionally, the methods comprise providing a biological sample from the subject and detecting in the sample a mutation in a IGH gene, wherein the mutation is in a nucleotide sequence encoding a complementarity determining region 3 (CDR3) of a IGH variable region. Optionally, the methods comprise determining a level of IgG specific for a galactose-deficient IgA1 in the subject. Also provided are methods of treating or reducing the risk of developing IgA nephropathy in a subject.Type: ApplicationFiled: April 24, 2017Publication date: December 21, 2017Inventors: Hitoshi Suzuki, Run Fan, Bruce A. Julian, Jan Novak, Zina Moldoveanu, Zhixin Zhang, Milan Tomana, Jiri Mestecky, Robert J. Wyatt, Yasuhiko Tomino, Yusuke Suzuki, Stephen Olson, Matthew B. Renfrow
-
Publication number: 20170360928Abstract: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.Type: ApplicationFiled: August 31, 2017Publication date: December 21, 2017Inventor: Robert D. Mass
-
Publication number: 20170360929Abstract: The present invention relates to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation comprising methionine and its pharmaceutical preparation and use. This invention is exemplified by a liquid formulation of an anti-Tumor Necrosis Factor alpha (TNF?) antibody.Type: ApplicationFiled: December 9, 2015Publication date: December 21, 2017Applicant: PFIZER INC.Inventors: Sandipan SINHA, Mariko AOKI
-
Publication number: 20170360930Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.Type: ApplicationFiled: August 31, 2017Publication date: December 21, 2017Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
-
Publication number: 20170360931Abstract: Provided herein are compositions useful for neutralization of influenza virus, and methods of use and manufacture thereof. In particular, compositions comprising antibodies that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.Type: ApplicationFiled: December 17, 2015Publication date: December 21, 2017Inventors: Patrick C. WILSON, Carole J. Henry DUNAND
-
Publication number: 20170360932Abstract: Methods for treating tumors by administering ionizing radiation and an immune modulator to a patient with cancer are disclosed. The methods provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining immune modulators with ionizing radiation to treat cancer patients. The methods described herein also allow for the classification of patients into groups for receiving optimized radiation treatment in combination with an immune modulator based on patient-specific biomarker signatures.Type: ApplicationFiled: June 16, 2017Publication date: December 21, 2017Applicant: Varian Medical Systems, Inc.Inventor: Renate Parry
-
Publication number: 20170360933Abstract: A medical nanoparticle includes a core, an outer lipid layer, an inner lipid layer, a photosensitizer, and a nucleic acid. The core includes a bio-degradable ionic precipitate (BIP). The inner lipid layer is between the core and the outer lipid layer. The photosensitizer is between the inner lipid layer and the outer lipid layer, and the nucleic acid is at the surface of the core.Type: ApplicationFiled: June 16, 2016Publication date: December 21, 2017Inventors: Leaf Huang, Yih-Chih Hsu, Gang Zheng, Chia-Hsien Yeh
-
Publication number: 20170360934Abstract: Provided herein are methods and pharmaceutical compositions for the treatment of obesity-associated conditions using cadherin-11 antagonists.Type: ApplicationFiled: December 15, 2015Publication date: December 21, 2017Applicant: The Brigham and Women's Hospital, Inc.Inventors: Michael B. Brenner, Sook Kyung Chang, Lydia Lynch
-
Publication number: 20170360935Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising -(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.Type: ApplicationFiled: December 10, 2015Publication date: December 21, 2017Applicant: PFIZER INC.Inventors: Kevin Richard Back, Michael Cram, Aidan James Harper, W. James Huang, Jonathan Richard Lillis, Timothy Michael Lukas, Sumit Luthra
-
Publication number: 20170360936Abstract: A humidity control device for use in maintaining the desired humidity of a closed environment, e.g., a container, while also decreasing headspace oxygen, the device including a water vapor and oxygen permeable pouch, an aqueous salt solution containing humidity controlling salts in combination with salts of ascorbic acid or isomers thereof.Type: ApplicationFiled: September 5, 2017Publication date: December 21, 2017Inventors: David C. Egberg, Robert L. Esse
-
Publication number: 20170360937Abstract: A pharmaceutical or cosmetic carrier for topical administration substantially consists of phosphatidylcholine, monoglyceride, fatty acid ester of C1-C3 alcohol; volatile solvent selected from ethanol and its combinations with C3-C4 alcohol and/or volatile silicone oil. Also disclosed are pharmaceutical and cosmetic compositions comprising the carrier and pharmaceutically or cosmetically active agent(s).Type: ApplicationFiled: November 6, 2014Publication date: December 21, 2017Applicant: LIPIDOR ABInventors: Bengt HERSLOF, Jan HOLMBACK
-
Publication number: 20170360938Abstract: The present invention relates to a composition containing carbohydrate partial esters, the preparation thereof and products containing the carbohydrate partial esters according to the invention.Type: ApplicationFiled: December 11, 2015Publication date: December 21, 2017Inventors: Stefan Busch, Eike Ulf Mahnke, Melina Machado Sincero, Markus Kloeker
-
Publication number: 20170360939Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection.Type: ApplicationFiled: June 29, 2017Publication date: December 21, 2017Inventors: Hyun Uk Kim, Hyung Kyu Lim, Myung Hyun Jang, Sang Yun Kim, Sung Min Bae, Se Chang Kwon